Int. J. Curr. Res. Med. Sci. (2025). 11(2): 1-12

International Journal of Current Research in Medical Sciences

ISSN: 2454-5716

(A Peer Reviewed, Indexed and Open Access Journal)

www.ijcrims.com

Review Article

Volume 11, Issue 2 -2025

DOI: http://dx.doi.org/10.22192/ijcrms.2025.11.02.001

A Review on Expanding Horizons: The Critical Role of Pharm.D Professionals in Antimicrobial Stewardship.

Dr.Mohammed Misbah Uddin[1], Riya Thakur[2], Ayush Pandey[3], Riya Patial[4], Mohammad Rizwana[5], Dr.Twinkle[6], Priyanka Reddy Pyatla[7], Dr.S.Tharun Raj[8], Dr. Syed Mohammed[9], Dr. Sumanth Raj Pasunoori[10]

[1]Pharm.D, princeshaik190@gmail.com

[2]Pharm.D, riyathakur200224@gmail.com

[3]Pharm.D, Ayushpandey7888@gmail.com

[4]Pharm.D, riyapatial73@gmail.com

[5]Pharm.D,rizzwanarizzu224@gmail.com

[6]Pharm.D, Twinklepundir51@gmail.com

[7]Pharm.D, priyankareddy93910@gmail.com

[8]Pharm.D, tharunraj1632@gmail.com

[9]Pharm.D, syedpatel8234@gmail.com

[10]Pharm.D, pasunurisumanthraj@gmail.com

*Corresponding author: Dr.Mohammed Misbah Uddin Pharm.D

Abstract

Antimicrobial resistance (AMR) is one of the most critical threats at the global level to public health and therefore requires a strong commitment to preventing any misuse of antimicrobial agents. This review presents the extended roles of Pharm.D professionals in antimicrobial stewardship (AMS) programs and highlights their critical contributions in optimizing the use of antimicrobials as well as combating AMR. Equipped with knowledge in pharmacology, therapeutics, and patient care, Pharm.D professionals are active members of multidisciplinary AMS teams through reviewing prescriptions; educating health care providers; monitoring patient outcomes; and using advanced diagnostic tools. The current review further discusses challenges, trends, and success stories of Pharm.D-led AMS initiatives. It posits future directions of AMS, including expanding AMS to outpatient settings and emphasizing global collaboration in the battle against AMR as well as leveraging advanced technologies. The review highlights how Pharm.D professionals are crucial in effective AMS planning for a future of healthcare sustainability.

Keywords: Antimicrobial Resistance, Antimicrobial Stewardship, Pharm.D Professionals, Healthcare Collaboration..

Introduction

AMR is one of the greatest threats to global health and has successfully undone many decades of progress in medicine and public health. Fast-evolving and quickly disseminated resistant microorganisms continue to make a large number of first-line antibiotics ineffective, increasing morbidity, mortality, and cost. This crisis needs a multifaceted and collaborative response from numerous agents.

AMR has been implicated in an alarming rise in difficult-to-treat infections, which could lead to a potential toll of 10 million lives each year by 2050 on an unchecked basis. Countries with low and middle incomes are disadvantaged due to poor availability of healthcare infrastructure and widespread misuse of antibiotics, and infection prevention is not sufficiently emphasized. The monumental loss is felt as healthcare systems experience longer hospitalizations, costly second-line alternatives, and an increase in mortality.[1,2] Antimicrobial stewardship programs are key in curbing AMR through improving the use of antibiotics with AMS. It works to optimize the choice, dosage, and duration of antimicrobials for a patient so that it acquires the best possible outcome while reducing risk of emerging resistance. Evidence-based guidelines and education and monitoring by AMS will create appropriate prescribing practices while improving the existing shelf life of antimicrobials.

Health professionals are fundamental to the operations of antimicrobial stewardship programs. They include clinical representatives from different areas, namely physicians, pharmacists, and nurses, with microbiologists available for diagnosis and distribution of antimicrobials. For example, pharmacists play a big role through prescription reviews and dose adjustments as well as education of patients and healthcare teams on potential antibiotic misuse. Interdisciplinary cooperation works well for driving AMS initiatives, implementing them, and sustaining them.[3,4]

Antimicrobial Stewardship (AMS)

Antimicrobial stewardship (AMS) is a systematic evidence-based approach to the optimization use of antimicrobials including antibiotics, antifungals, antivirals, and antiparasitics to face the major challenge posed by growing antimicrobial resistance (AMR). It balances goal of effectively treating infections with that of preserving agents in the long run. AMS cuts across all facets of clinical care, microbiology, pharmacology, and public health in that it seeks to improve patient outcomes while minimizing adverse event effects, including resistance.

Principles of AMS

1. **Optimization of Antimicrobial Use**: Ensuring the right anticrobials are selected with the right dose, route, and duration, according to specific infection and circumstances for each patient.
2. **Prevention of over treatment and under treatment:** Avoiding unnecessary or inappropriate use of antimicrobials, such as the treatment of a viral infection.
3. **Retention of Antimicrobial Efficacy**: Slow emergence of resistance through prudent use of existing ones.
4. **Resuction of Adverse Outcomes**: Reducing the risk of side effects, including C. difficile infection, and limiting the spread of resistant pathogens within the healthcare settings.[5,6,7]

Goals of Antimicrobial Stewardship (AMS) Programs

1. Improve Patient Outcomes

The primary goal of the AMS program is to ensure that patients receive effective treatments for their infections. AMS programs help do this by guiding a selection of antimicrobials optimized for addressing specific infections in conjunction with a patient's condition, allowing for rapid recovery, fewer complications, and reduced mortality. This ensures that the right drug, dose, route of administration, and duration of therapy

added would enhance clinical outcomes by reducing risks from and about treatment failure and poor patient prognosis.

2. Reduce Antimicrobial Resistance (AMR)

AMR has created one of the strongest pulls in terms of global health threats. Among the important strategies to combat AMR is the establishment of proper antimicrobial use practices rather than unbridled control of its availability. Development of resistant organisms occurs faster in conditions where antimicrobials are used unnecessarily or inappropriately. AMS involves inappropriate use of antimicrobials for viral infections and appropriate deescalation of therapy. As such, rationalizing antimicrobials through AMS will reduce selective pressure to pathogens: yeast, slowing the development of resistant strains, and preserving current antimicrobials' effectiveness.[8,9]

3. Enhance Patient Safety

AMS programs play important roles in the fortification of patient safety by preventing the adverse effects of inappropriate use of antimicrobials. This includes the antifungal features such as yielding to less nephrotoxicity, hepatotoxicity, or allergic reactions resulting from improper use of antimicrobials. AMS also saved secondary infections such as those caused by Clostridioides difficile associated primarily with broader-spectrum antibiotic use, which can make the patient suffer more. With the right selection and dose of antimicrobials, AMS contributes to overall safety in the care of patients and subsequent complications as well as harms from treatment.

4. Promote Cost-Effective Care

AMS programs contain costs to health systems with appropriate antimicrobials. Overuse and inappropriate prescribing of antimicrobials always result not only in the excessive cost of buying the antibiotics but also by the long stay in hospitals and treatment of complications arising from resistant infections. Cost-effective first-line therapies that shorten these unnecessary treatments and promote their use are some activities of AMS programs that reduce the economic burden on healthcare systems. Also preventing infection and reducing resistant strains decreases their management costs over time, making them tracing-only infections.

5. Preserve Antimicrobial Efficacy for Future Use

The primary purpose of AMS is to maintain the long-term potency of an antimicrobial agent. Given the slow accretion of new antimicrobials, it becomes necessary to extend the efficacy of already existing antibiotics for use by the next generation. This can be achieved in AMS programs by ensuring that such antibiotics are used appropriately and that broad-spectrum agents are reserved for incidences when there is no alternative for the case concerned. Through reducing overuse and misuse of antimicrobials, AMS will help prevent the development of resistance and ensure current antimicrobial therapies work for future infections.

6. Strengthen Infection Prevention and Control (IPC)

Infection Prevention Control, or IPC, is at the heart of AMS programs because it is reducing the need for antimicrobials that comes right after infection. Vaccination, improved hand hygiene, and isolation protocols for patients with resistant infections, in addition to such practices AMS promotes, reduction of infections treated with antimicrobials, together with infection prevention and control. IPC and AMS work hand in hand to address the total burden regarding infection, as this will therefore definitely lower the use of antibiotics and, further, the necessitated development of resistance. The two put together render a holistic infection management and antimicrobials stewardship strategy.[10,11,12]

Strategies and Interventions In AMS

1. Evidence-Based Guidelines and Protocol

Developing and adhering to the evidence-based guidelines in treatment protocol is one of the

cornerstones of antimicrobial stewardship (AMS). It helps the clinician in deciding which antimicrobials are appropriate according to the local resistance pattern, type of infection and characteristics of patients. Standardization of therapies allows AMS programs prescribing antimicrobials based on standardized protocols according to the best available evidence, which helps in selecting the right drug, dose and duration of therapy. It reduces the chances of misuse and promotes rational medication selection which is very important in combating antimicrobial resistance (AMR).

2. Diagnostic Stewardship

Another important norm or paradigm shift of AMS is diagnostic stewardship. It embarks on improving patient diagnosis to facilitate appropriate antibiotic usage. Accurate identification and precise rapid identification of pathogens are required for the selection of appropriate therapy. For instance, diagnostic stewardship would involve more of using advanced diagnostic tools such as molecular testing and biomarker assays to distinguish bacterial from viral infections. Diagnostic stewardship thus recommends reducing empirical prescribing and deescalation of therapy to already prescribed ones once the pathogen is identified. For timely use of diagnostics, this AMS practice would thus decrease unnecessary antimicrobial usage, resulting in reduced chances of resistance development.

3. Antimicrobial Monitoring and Feedback

This is an integral AMS intervention: monitoring the use of antimicrobials and feeding back to health personnel information on the use. It involves audit of antimicrobial prescription for inappropriate use followed by real-time feedback to prescribers on their prescribing patterns. Apart from regular audits, feedback can also be given in real time to clinicians as they capture when a certain antimicrobial is prescribed and for what reason and check how it matches up with what internationally recommended best practice guidelines state. Monitoring also involves tracking outcomes to demonstrate that prescribed therapies are producing beneficial, desired clinical results. By feedback, AMS programs ensure adherence to guidelines and improvements in appropriate prescriptions over time.[13,14,15]

4. Education and Training

Educational initiatives form the backbone of successful AMS programs. Continuous education at the level of healthcare professionals (doctors, pharmacists, and nurses) is required for improving the understanding on issues related such as antimicrobial resistance, optimal prescriptions, and the role of AMS in improving patient outcome. Regular required training sessions usually deal with concepts like when antibiotics are needed, the need of de-escalating, and how to interpret microbiological data. Educating patients forms another element that helps sensitize patients about the consequences of overuse and also the need to adhere to prescribed regimens, thus helping in reducing demand for unnecessary antibiotics.

5. Optimization of Antimicrobial Therapy

Antimicrobial optimization forms a core part of all AMS programs: the use of the most effective therapy, while reserving it for unjustified occasions of application. Examples of interventions aimed at improving therapy include de-escalation from empirical broad-spectrum coverage to narrow coverage based on culture and sensitivity results, switching from intravenous anti-infectives to oral at an appropriate point in the course of treatment, and shortening the duration of therapy when possible. These types of activities have the advantage of preventing resistance and limiting adverse drug reactions, as well as costs for prolonged or unnecessarily high levels of antimicrobial therapy.[16,17]

Role of AMS in Optimizing Clinical Outcomes and Reducing Resistance

Optimizing Clinical Outcomes

AMS is crucial in optimizing clinical outcomes through effective antimicrobial therapy, targeted indications and doses. AMS promotes the right

drug to be instituted for an infection while ensuring correct dosage and duration, improving the chances of successful treatment, faster recoveries, and fewer complications. It should be noted that early and precise antimicrobial interventions involve increased risk of treatment failure, readmissions, and prolonged hospitalization, impacting the outcome. Besides, AMS minimizes the procurement of secondary infections such as C. difficile or fungal infections resulting from broad-spectrum antimicrobials. After all, AMS treatments are more safe and effective, leading to increased recovery rates and better health outcomes.

Reducing Resistance

The inappropriate usage of antimicrobial agents leads directly to the development of AMR. AMS programs focus on appropriate and proper use of antimicrobials, meaning they should only be used when required, at appropriate dosages, and for the intended duration. Such strategies include de-escalation (narrowing the spectrum of antibiotic therapy based on tests), narrow-spectrum agents, and short-term therapy; they reduce the selective pressure on bacteria, a major factor in the development of resistance. Broad-spectrum antibiotics, for example, increase the risk of resistance since they target more bacteria than necessary Therefore, AMS reduces unnecessary exposure to antimicrobials. It decelerates resistance progression, maintains efficacy among current antimicrobials, and avoids resistant pathogen emergence. In addition, AMS minimizes infection prevention measures, further reducing the pressure for antimicrobial treatment and contributing to overall concentration control of resistant organisms.[18,19]

The Role of Pharm.D Professionals in Antimicrobial Stewardship (AMS)

Pharm.D professionals occupy a very important position in antimicrobial stewardship (AMS) programmes. Their skills in pharmacology, pharmacotherapy and clinical practice come in handy for the use optimization of antimicrobial agents within the programmes. They are the major consideration for administering a therapy right or monitoring the efficacy of treatment and contributing to the broader AMR goals of reduction.

1. Medication Management and Optimization

Doctor of Pharmacy professionals are experts in the optimal management of antimicrobials. It helps the patients in making good decisions related to antimicrobial agents based on the clinical conditions, types of infection, and micro-organism data of the patient presented. In combination with some other parameters, Pharm.D professionals tailor the therapy by drug interactions, renal or hepatic function, and possible adverse effects. They assist with the correct dosage, duration, and route of administration, which would form the foundation to underwrite the minimization or prevention of the subtherapeutics or overuse of the antimicrobials. The Pharm.D professionals optimize the treatment regimen for improved clinical outcomes, reduced emergence of resistance, and enhanced patient safety.[20,21]

2. Antimicrobial Stewardship Guidelines and Protocol Development

Pharm.D professionals are engaged in developing, reviewing, and implementing antimicrobial stewardship guidelines and protocols instituted within their respective institutions. They help in writing evidence-based guidelines for selecting, dosing, and de-escalating antimicrobials through their knowledge of pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring. They also participate in many interdisciplinary teams that relate local resistance patterns with treatment recommendation guidelines on prescribing. This feature also touches on updating the protocols to include new antimicrobial agents, new trends in resistance, and clinical research outcomes in the future.

3. Monitoring and Surveillance of Antimicrobial Use

The Role of Pharm.D in the Determination and Use of Approved Therapy in Health Care Services Evidence-Research Involvement of Pharm.Ds in

Surveilling Antimicrobial Use in Healthcare Settings Active functions assign to Pharm.Ds such as patient records, reviewing therapy and evaluating appropriateness of treatment in patients, and monitoring for intervention. Reviewing the patient records, medication charts and microbiology reports about the patients allows Pharm.D professionals to identify instances when inappropriately broad-spectrum agents were prescribed or antibiotics administered to treat viral infections. Such incidences need to be flagged to assess clinical outcomes and relay feedback to improve antimicrobial use over time.

4. Providing Education and Training

Empowerment of others through Pharm.D and development of training programs in regard to antimicrobial stewardship principles, appropriate antibiotic usage, resistance patterns, and current research in infectious disease management are kept going to research health care providers-such as doctors, nurses, as well as other pharmacists-along therewith. Moreover, Pharm.D professionals handle educational issues pertinent to patients as far as antimicrobial use and adherence to prescribed regimens are concerned. These patients are expected to benefit in terms of reduction of unnecessary antibiotic demands referred to as developing drugs and their effectiveness in patient outcomes. However, by nurturing a culture of continuous learning within Pharm.D professionals, they amplify the already existing efficiency of the AMS.[22,23,24]

5. Antibiotic Prescription Review and Clinical Consultation

Even Pharm.D specialists routinely examine patient prescriptions for antibiotics. They assess the high necessity for antibiotics in hospitals and with outpatients, advise on use of most effective agents, and recommend alternative therapies where necessary. The duties include advising on selection of antimicrobials with respect to the local resistance patterns, consulting on de-escalation or step-down therapy, and ensuring that the drug therapy is consistent with all patient-individual factors like allergy status, comorbidities, and clinical status. As a plus, Pharm.D professionals serve as an invaluable resource for clinicians when drawing complex therapeutic decisions, thus promoting reduced unnecessary antimicrobial uses and minimizing development of resistance.

6. De-Escalation of Antimicrobial Therapy

Pharm.D professionals will offer their roles in the de-escalation of antimicrobial therapy that may change from broad-spectrum antibiotic formulations to narrower-spectrum ones. This is made possible when the results of the microbiological culture are obtained. This is another area that can limit the development of antimicrobial resistance caused by unnecessary exposure to broad-spectrum agents. Such adjustment is timely, and it allows for possible changes to the antimicrobial regimen via reviewing the microbiological data and the patient's progress so far. With this intervention avenue, development of resistance is minimized, while adverse drug reactions due to broad-spectrum antibiotics are also probably lessened.

7.Therapeutic Drug Monitoring (TDM)

Therapeutic Drug Monitoring (TDM) involves pharmaceutical professionals in AMS in collaboration with narrow therapeutic antimicrobials such as vancomycin, aminoglycosides, and some antifungal agents in order to optimize their efficacy and minimize the risk of toxicity or therapeutic failure. TDM entails maintenance of drug levels in the therapeutic ranges. In addition, Pharm.D professionals interpret drug levels, adjust doses accordingly, and monitor the patient's clinical responses to ensure that antimicrobial therapy remains effective and safe. This intervention is especially needed for patients who have altered pharmacokinetics, for example, those who have renal or hepatic impairment, because standard dosing may not be sufficient.[25,26,27]

8. Advancing Research and Evidence-Based Practice

The involvement of the Pharm. D. professionals in research related to AMS contributes to the results obtained in various studies assessing the

effectiveness of interventions in AMS or related to the trends of antimicrobial resistance, and new treatment alternatives for resistant infection. By keeping abreast of the most recent clinical and pharmacological developments, Pharm.D professionals ensure that all AMS efforts are well pointed towards the most recent and most relevant data. The research involvement also aids in coming up with new ideas to make better use of antimicrobials and solutions to the different problems related to resistance.

9. Multidisciplinary Collaboration

Programs for AMS are inevitably interdisciplinary; they involve collaboration among Pharm.D professionals and other health-care providers or specialists such as that of infectious diseases, microbiology, medicine, and nursing. Members share their perspectives on the importance of pharmacology within AMS teams to ensure pathogen-based drug formulations comply with current guidelines and resistance data, besides being a critical member of the AMS team. This cooperation also includes collaboration with other healthcare professionals to put in place stewardship measures, evaluate success rates from AMS interventions, troubleshoot antimicrobial use problems, and so on. Such an approach guarantees all-rounded collaboration and the coordinated endeavor to combat AMR and care optimization.

10. Advocating for Infection Prevention and Control

These are further impressive realms in which Pharm.D professionals would be active advocates: the promotion of infection prevention and control practices that keep in check the even further requirement of antimicrobials. They promote practices such as appropriate hand hygiene, vaccination, safe handling of medical devices, and patient isolation when warranted. Invasive procedures tend to have the greatest burden in creating hospital-acquired infections. With IPC, a reduction in the number of hospital-acquired infections would lead to a corresponding reduction in demand for therapeutic antimicrobials and the development of resistance.[28,29]

11. Cost Reduction and Healthcare Resource Optimization

Cost-effective antimicrobial stewardship programs delivered by Pharm.Ds would thus actually help in reducing healthcare costs by fine-tuning antimicrobial use. Reducing the use of broad-spectrum antibiotics, shortening courses of unnecessary therapy, and preventing complications from overuse of antimicrobials (for example, resistance, ADRs, or superinfections), would reduce healthcare costs through associated savings in lowered morbidity and mortality. These input-enhanced direct or indirect savings in healthcare expenditure further lead by Pharm.D professionals involved in improving clinical outcomes and infection prevention, which, in turn, lead to a shorter hospital stay and a reduced need for high-cost interventions such as admission to closed-acuted-care units or protracted regimens of high-cost antibiotics.

Challenges Faced By Pharm.D Professionals In AMS

Institutional Barriers

Sometimes the AMS program may not be fully endorsed or embedded in the organization such that Pharm.D professionals can become a part of it. Such a program without the full backing institution is difficult to be run successfully, and Pharm.D professionals will find it hard to participate in various antimicrobial management decision.

Time Constraint

The Pharm.D professional busies himself providing patient care, counseling, and many other activities. Limited time focusing on AMS would hinder a thorough antimicrobial review, health provider education, and outcome monitoring.[30,31]

Training Gaps

Most Pharm.D professionals have knowledge of almost everything concerning pharmacology, but some have limited knowledge or experience in

certain themes of AM. Continuous education and specialized training in practices of antimicrobial resistance (AMR) and stewardship are important; however, they may not always be readily available, making it difficult for these professionals to keep up to date with contemporary practices.

Resistance from Healthcare Providers

Occasionally, doctors or nurses might resist Pharm.D recommendations owing to a misunderstanding of what they stand for or a sheer resistance of changing established practices. This may even hamper internal collaboration within AMS teams and weaken the success of stewardship interventions.

Data Limitations

Effective AMS calls for timely and accurate data that include microbiological results and patient outcomes. Pharm.D has problems getting access to the necessary data for making decisions on antimicrobial therapy and for monitoring the outcome of AMS programs.

Complex Patient Cases

Pharm.D usually can be seen dealing with patients having multiple ailments or taking medications from more than one class. These complicated cases make it difficult to define the therapy for antimicrobial and adverse drug reactions and drug interactions. These require special care in dealing with them.

Policy Barriers

In certain jurisdictions, legal or regulatory constraints restrict the power of Pharm.D professionals to authorize modification to or adjustment of antimicrobial prescriptions. This might consequently slow the response to infection and limit the efficacy of AMS initiatives, particularly in critical cases.

Financial Barriers

Implementation of AMS programs such as hiring and training staff and using sophisticated diagnostic tools is limited due to lack of finances. Additionally, the intention of carrying out stewardship activities will not be realized by Pharm.D professionals without adequate funds, resources, or support.[32,33]

Emerging Trends In AMS and The Role of Pharm.D Professionals

1. Advanced Diagnostic Tools

Innovative rapid diagnostics are enabling healthcare practitioners to quickly identify pathogens and their resistance profiles, making possible better-targeted, more effective therapy. They assist Pharm.D professionals collaborate with AMS programs to interpret diagnostic result findings and counsel antimicrobial therapy.

2. Personalized Medicine and Pharmacogenomics

Even now, modern personalized medicine in all of its manifestations requires that treatments be adapted according to the individual patients' characteristics, especially their genetic profile. They further guide the best potential course of antimicrobial therapy for each patient using pharmacogenomics technology to provide the most effective treatment without the risks of resistance.

3. AMS in Outpatient Care

AMR is an issue of great concern in outpatient care, just as it is in hospitals. Pharm.D professionals are expanding their roles by accommodating responsibilities as primary care practitioners who educate both patients and other health providers on the appropriate use of antibiotics for common infections to prevent their overuse.[34,35]

4. Global Collaboration and Policy Development

It is a conscious international issue; there cannot be survival beside national boundaries. Maria Pharm.D has also been able to reshape AMS policies and guidelines at national and

international levels to match harnessing efforts in curbing resistance attributed to shared best practices across nations.

5. AMS in Long-Term Care

Long-term care residents receive excessive antibiotics, making these facilities ideal settings in the battle against AMR. Pharm.D professionals play a key role in optimizing the use of antimicrobials and preventing the infection of this traditionally susceptible population..

6. Environmental Impact of AMR

Antibiotics in the environment and especially wastewater promote resistance to this chemical compound. Pharm.D would help train health settings on the right disposal methods and make sustainable practices in a pharmaceutical company for reducing environmental contamination.

7. AI and Machine Learning in AMS

AI and machine learning are now used for the prediction of infection outcomes and, thus, to optimize antimicrobial use. The expertise of Pharm.D professionals should then be solicited to build an evidence-based treatment for improved efficiency of AMS intervention in these technologies.[35,36]

Future Directions and Recommendations in AMS

1. Integration of Advanced Technologies

Infection outcome prediction and optimization of antimicrobial therapy, using advanced technologies like AI and machine learning, is possible. AMS programs within those technologies have their focus in making such decisions increase in patient care and reduce resistance.

2. Expanding AMS to Outpatient and Primary Care Settings

History has seen AMS programs focusing heavily on hospitals. However, with the upsurge of AMR among the outpatients, an extension to primary care and community pharmacies becomes imperative. Educating patients and healthcare providers regarding appropriate antibiotic use in any of these settings can be an area of advancement for Pharm.D.

3. Global Collaboration

AMR is a worldwide concern. Therefore, countries should exchange data on antimicrobial resistance patterns and come up global policy and guidelines to curb it. They should also involve Pharm.D professionals as contributors to these global health initiatives intended to ensure that AMS practices are involved worldwide.[37,38]

4. Personalized Medicine

Much personalized medicine is coming down ever-increasingly specialized treatments for individuals. Personalizing antibiotics based on this could have meanings, including genetic testing and rapid diagnostics, for ensuring the correct prescription of antibiotics to the correct patients at the correct time, reducing resistance risk.

5. Focus on Education and Training

One such ongoing education and training project for all practitioners, including Pharm.D, is vital for being updated according to all the latest AMS core principles and practices. Such workshops, webinars, and training programs conduct FAQs that help improve knowledge and skills among health practitioners to implement the strategies successfully.

6. Public Awareness Campaigns

Strategically, public awareness on the threat of misuse of antibiotics has to be raised in regard to the AMS programs currently designed to include educational campaigns targeted on responsible antibiotic use by the general public to reduce unnecessary prescriptions.

7. Strengthening Surveillance Systems

Identification of trends and actions in this respect requires improved surveillance for antimicrobial

use and resistance patterns: investment of AMS program in strengthening surveillance systems at localized, national and global levels should track the current effectiveness of strategies and improvements to be made.

8. Collaboration with Regulatory Bodies

Pharm.D professionals can participate with regulatory agencies for following antimicrobial prescriptions guidelines and updating policies as suggested by evidence. Collaboration can facilitate the establishment of a national, regional and international policy on antibiotic use and resistance[39,40].

Conclusion

The conclusion of this study suggests that the role of Pharm.D professionals in AMS programs is that of an evolving central player as they are one of the key inputs against AMR. Their stronghold in pharmacology, patient care, and therapeutic decision-making is relevant to the effectiveness of AMS in various health settings. The activities of Pharm.D professionals in optimizing their role for better patient outcomes include prescription reviews, patient education, outcome monitoring, and adaptation of advanced technologies to maximize the use of antimicrobial agents. The growing threat of AMR at the international level will count for the future of AMS to a large extent on the continued expansion of the Pharm.D role, application of creative diagnostic and therapeutic strategies, and enhanced global collaboration. Strengthening the involvement of Pharm.D professionals in AMS will undoubtedly be critical to the long-term effectiveness of antimicrobial treatment and public health worldwide.

References

1. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MAA. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare (Basel). 2023 Jul 5;11(13):1946.
2. Williams-Nguyen J., Sallach J.B., Bartelt-Hunt S., Boxall A.B., Durso L.M., McLain J.E., Singer R.S., Snow D.D., Zilles J.L. Antibiotics and Antibiotic Resistance in Agroecosystems: State of the Science. J. Environ. Qual. 2016;45:394–406.
3. Morency-Potvin P, Schwartz DN, Weinstein RA. Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the Ship. Clin Microbiol Rev. 2016 Dec 14;30(1):381-407.
4. Lepper MH. 1955. Microbial resistance to antibiotics. Ann Intern Med 43:299–315.
5. Doron S, Davidson LE. Antimicrobial stewardship. Mayo Clin Proc. 2011 Nov;86(11):1113-23
6. Dellit TH, Owens RC, McGowan JE, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM., Infectious Diseases Society of America. Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007 Jan 15;44(2):159-77.
7. Patel D, Lawson W, Guglielmo BJ. Antimicrobial stewardship programs: interventions and associated outcomes. Expert Rev Anti Infect Ther. 2008 Apr;6(2):209-22.
8. Walia K, Ohri VC, Madhumathi J, Ramasubramanian V. Policy document on antimicrobial stewardship practices in India. Indian J Med Res. 2019 Feb;149(2):180-184.
9. Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global targets for antimicrobial resistance. Science. 2016;353:874–5.
10. File TM Jr, Srinivasan A, Bartlett JG. Antimicrobial stewardship: importance for patient and public health. Clin Infect Dis. 2014 Oct 15;59 Suppl 3(Suppl 3):S93-6
11. Fridkin SK, Srinivasan A. Implementing a strategy for monitoring inpatient antimicrobial use among hospitals in the United States. Clin Infect Dis 2014; 58:401–6.
12. Thursky KA, Hardefeldt LY, Rajkhowa A, Ierano C, Bishop J, Hawes L, Biezen R, Saha SK, Dowson L, Bailey KE, Scarborough R, Little SB, Gotterson F, Hur B, Khanina A, Urbancic K, Crabb HK, Richards S, Sri A, James R, Kong DCM, Marshall C, Mazza D,

Peel T, Stuart RL, Manski-Nankervis JA, Friedman ND, Bennett N, Schulz T, Billman-Jacobe H, Buono E, Worth L, Bull A, Richards M, Ayton D, Gilkerson JR, Browning GF, Buising KL; National Centre for Antimicrobial Stewardship. Antimicrobial stewardship in Australia: the role of qualitative research in programme development. JAC Antimicrob Resist. 2021 Nov 18;3(4):dlab166.

13. Patel SJ, Saiman L. Principles and strategies of antimicrobial stewardship in the neonatal intensive care unit. Semin Perinatol. 2012 Dec;36(6):431-6
14. Claeys KC, Johnson MD. Leveraging diagnostic stewardship within antimicrobial stewardship programmes. Drugs Context. 2023 Feb 20;12:2022-9-5.
15. Nampoothiri V, Mbamalu O, Mendelson M, Singh S, Charani E. Pharmacist roles in antimicrobial stewardship: a qualitative study from India, South Africa and the United Kingdom. JAC Antimicrob Resist. 2024 May 6;6(3):dlae047.
16. Tinker NJ, Foster RA, Webb BJ, Haydoura S, Buckel WR, Stenehjem EA. Interventions to optimize antimicrobial stewardship. Antimicrob Steward Healthc Epidemiol. 2021 Nov 10;1(1):e46.
17. Vitrat V, Hautefeuille S, Janssen C, Bougon D, Sirodot M, Pagani L. Optimizing antimicrobial therapy in critically ill patients. Infect Drug Resist. 2014 Oct 20;7:261-71.
18. Al-Omari A, Al Mutair A, Alhumaid S, Salih S, Alanazi A, Albarsan H, Abourayan M, Al Subaie M. The impact of antimicrobial stewardship program implementation at four tertiary private hospitals: results of a five-years pre-post analysis. Antimicrob Resist Infect Control. 2020 Jun 29;9(1):95.
19. Khadse SN, Ugemuge S, Singh C. Impact of Antimicrobial Stewardship on Reducing Antimicrobial Resistance. Cureus. 2023 Dec 4;15(12):e49935.
20. Nampoothiri V, Mbamalu O, Mendelson M, Singh S, Charani E. Pharmacist roles in antimicrobial stewardship: a qualitative study from India, South Africa and the United Kingdom. JAC Antimicrob Resist. 2024 May 6;6(3):dlae047.
21. Jantarathaneewat K, Camins B, Apisarnthanarak A. The role of the clinical pharmacist in antimicrobial stewardship in Asia: A review. Antimicrob Steward Healthc Epidemiol. 2022 Nov 7;2(1):e176
22. Dickerson LM, Mainous AG 3rd, Carek PJ. The pharmacist's role in promoting optimal antimicrobial use. Pharmacotherapy. 2000 Jun;20(6):711-23.
23. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005 Oct;18(4):638-56.
24. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM, Ramsay CR, Michie S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD003543
25. Pasquau-Liaño J, Sadyrbaeva-Dolgova S, Sequera-Arquellada S, García-Vallecillos C, Hidalgo-Tenorio C. Timing in antibiotic therapy: when and how to start, de-escalate and stop antibiotic therapy. Proposals from a stablished antimicrobial stewardship program. Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):102-107.
26. Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol. 2012 Jan;73(1):27-36.
27. Dighriri IM, Alnomci BA, Aljahdali MM, Althagafi HS, Almatrafi RM, Altwairqi WG, Almagati AA, Shunaymir AM, Haidarah GA, Alanzi MH, Hadadi AA, Suwaydi HM, Aqdi MJ, Alharthi HN, Alshahrani AF. The Role of Clinical Pharmacists in Antimicrobial Stewardship Programs (ASPs): A Systematic Review. Cureus. 2023 Dec 8;15(12):e50151.
28. Taplitz RA, Ritter ML, Torriani FJ. Infection Prevention and Control, and Antimicrobial Stewardship. Infectious Diseases. 2017:54–61.e1.
29. Chetty S, Swe-Han KS, Mahabeer Y, Pillay A, Essack SY. Interprofessional education in antimicrobial stewardship, a collaborative effort. JAC Antimicrob Resist. 2024 Apr 1;6(2):dlae054.
30. Giamarellou H, Galani L, Karavasilis T, Ioannidis K, Karaiskos I. Antimicrobial Stewardship in the Hospital Setting: A

Narrative Review. *Antibiotics*. 2023; 12(10):1557.
31. Mathew P, Ranjalkar J, Chandy SJ. Challenges in Implementing Antimicrobial Stewardship Programmes at Secondary Level Hospitals in India: An Exploratory Study. Front Public Health. 2020 Sep 18;8:493904.
32. Asante KP, Boamah EA, Abdulai MA, Buabeng KO, Mahama E, Dzabeng F, et al. Knowledge of antibiotic resistance and antibiotic prescription practices among prescribers in the Brong Ahafo Region of Ghana; a cross-sectional study. BMC Health Serv Res [Internet]. (2017) 17:2.
33. Cross AJ, Elliott RA, Petrie K, Kuruvilla L, George J. Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. Cochrane Database Syst Rev. 2020 May 8;5(5):CD012419.
34. Apisarnthanarak A, Bin Kim H, Moore LSP, Xiao Y, Singh S, Doi Y, Kwa AL, Ponnampalavanar SSS, Cao Q, Kim SW, Lee H, Santanirand P. Utility and Applicability of Rapid Diagnostic Testing in Antimicrobial Stewardship in the Asia-Pacific Region: A Delphi Consensus. Clin Infect Dis. 2022 Jun 10;74(11):2067-2076.
35. Hermsen ED, Jenkins R, Vlaev I, Iley S, Rajgopal T, Sackier JM, Loubser P, Pronk N, Wilkinson E, Chow Y, Gunther C. The Role of the Private Sector in Advancing Antimicrobial Stewardship: Recommendations from the Global Chief Medical Officers' Network. Popul Health Manag. 2021 Apr;24(2):231-240.
36. Pinto-de-Sá R, Sousa-Pinto B, Costa-de-Oliveira S. Brave New World of Artificial Intelligence: Its Use in Antimicrobial Stewardship-A Systematic Review. Antibiotics (Basel). 2024 Mar 28;13(4):307
37. De Corte T, Van Hoecke S, De Waele J. Artificial Intelligence in Infection Management in the ICU. Crit Care. 2022 Mar 22;26(1):79.
38. Pennisi F, Pinto A, Ricciardi GE, Signorelli C, Gianfredi V. Artificial intelligence in antimicrobial stewardship: a systematic review and meta-analysis of predictive performance and diagnostic accuracy. Eur J Clin Microbiol Infect Dis. 2025
39. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018 Jun;109(6):952-963
40. Jantarathaneewat K, Camins B, Apisarnthanarak A. The role of the clinical pharmacist in antimicrobial stewardship in Asia: A review. Antimicrob Steward Healthc Epidemiol. 2022 Nov 7;2(1):e176.

Access this Article in Online	
	Website: www.ijcrims.com
Quick Response Code	Subject: Public Health
DOI: 10.22192/ijcrms.2025.11.02.001	

How to cite this article: Mohammed Misbah Uddin, Riya Thakur, Ayush Pandey, Riya Patial, Mohammad Rizwana, Twinkle, Priyanka Reddy Pyatla, S.Tharun Raj, Syed Mohammed, Sumanth Raj Pasunoori. (2025). A Review on Expanding Horizons: The Critical Role of Pharm.D Professionals in Antimicrobial Stewardship. Int. J. Curr. Res. Med. Sci. 11(2): 1-12.
DOI: http://dx.doi.org/10.22192/ijcrms.2025.11.02.001